Lila Hope


+1 650 843 5735

Lila Hope focuses on the representation of life sciences companies discovering, developing and marketing pharmaceutical, vaccine, medical device, diagnostic and digital health products. She counsels clients ranging from privately-held companies to Fortune 500 companies. Lila specializes in transactions involving complex intellectual property, business, operational and legal issues, including strategic partnerships, discovery and option deals, and complex asset purchases. In addition, she counsels clients' management, operational and legal teams on matters involving licensing, supply, distribution, clinical trials, research collaborations and vendor services. She is also regularly involved in the evaluation of a company's product rights and operational risks in connection with financing, public offering and M&A transactions, including over 20 initial public offerings. In addition, she maintains an active practice in cross-border licensing transactions, including 18 transactions involving Asian biotechnology companies between 2015 and 2020.

Download full bio


  • I-Mab Enters Global Strategic Partnership With AbbVie for Cancer Treatment 

  • CardioKinetix Completes $50 Million Financing 

  • Adamas Pharmaceuticals Initial Public Offering 

  • Ascendis Pharma closes $124 million IPO 

  • Nexvet Biopharma Closes Initial Public Offering 

  • View all


  • Duke University School of Law
    JD, magna cum laude, 2002

  • Stanford University
    PHD, Cancer Biology

  • Oregon Graduate Institute
    MS, 1993

Admissions & Credentials



  • American Bar Association

Rankings & Accolades

    Chambers USA: Life Sciences - Corporate/Commercial

    Legal 500: Healthcare: Life Sciences


+1 650 843 5735 office
+1 650 849 7400 fax

3175 Hanover Street
Palo Alto, CA 94304-1130